English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
The Psychedelic Startup Boom: Who's Actually Building the Future of Plant Medicine
If you've spent any time researching ayahuasca, psilocybin, or ketamine-assisted therapy lately, you've probably noticed something odd. The field used to feel like a whisper network — a friend of a friend who knew a curandero, a quiet retreat tucked into the Dutch countryside, a clinical trial you needed three referrals to enter. Now there are venture-backed startups, telehealth platforms, and biotech labs trying to engineer the next generation of compounds. The money has arrived. So have the spreadsheets. For someone weighing whether to book a psychedelic retreat or try plant medicine for addiction, depression, or just the slow grind of feeling stuck, this matters. The companies getting funded right now will shape what's available to you in the next few years — the protocols, the prices, the credentialing of facilitators, even whether your insurance ever picks up the tab. So it's worth knowing who they are and what they're actually doing. Here's a tour of seven companies that investors have flagged as movers in the space, plus some honest thoughts on what their existence means for people considering a real-life journey. Analysts have thrown around forecasts that the psychedelic treatment market could eventually clear nine figures globally. Whether that number holds or not, the underlying logic is real: depression rates aren't dropping, SSRIs work for some people and fail others, addiction continues to gut families, and the existing mental-health system is buckling. Psychedelics — used carefully, with skilled support — have shown enough promise in clinical trials that smart capital wants in. What that means in practice is a wave of startups doing very different things. Some are trying to design molecules. Some are training therapists. Some are building software for clinics. And a few are doing what humans have done for thousands of years — running retreats with master plants and trained facilitators, just with a website and a Stripe account attached. Based in Boston and founded in 2019, Delix raised north of $100 million working on what they call psychoplastogens — compounds inspired by psychedelics but engineered to skip the trip. The idea is to capture the neuroplasticity benefits (the brain-rewiring part that seems to do a lot of the therapeutic work) without the six-hour experience of ego dissolution. Early animal research suggests these compounds may even reverse cortical atrophy. Whether you find that exciting or vaguely depressing probably says a lot about your worldview. For people who can't take time off work, can't tolerate altered states, or have medical contraindications, a non-hallucinogenic option is genuinely important. For those who believe the mystical experience itself is the medicine, it's a harder sell. Out of Woodstock, New York, Fluence trains psychiatrists, therapists, and social workers in psychedelic-assisted therapy and integration. They raised a modest $3 million seed round, but their work matters disproportionately. The single biggest bottleneck for legal psychedelic therapy isn't the drugs — it's the people qualified to sit with you while you take them. If you've ever wondered why finding a competent psychedelic-informed therapist feels harder than finding a unicorn, this is why. The training pipeline is tiny. Companies like Fluence are trying to fix that. Toronto-based and only a few years old, Homecoming is a digital companion for the period before and after a psychedelic session. Think daily check-ins, journaling prompts, structured integration tasks, and a way for your therapist to see how you're actually doing between appointments. This is the unsexy part of psychedelic work that almost everyone underestimates. The ceremony is loud and dramatic. Integration — the quiet weeks afterward when you're trying to actually change something about your life — is where the work really lands or doesn't. New York-based Journey Clinical built a decentralized model for ketamine-assisted psychotherapy. Your existing therapist — the one who already knows your story — partners with their in-house medical team, who handles eligibility screening, prescribing, and clinical monitoring. You don't have to start over with a stranger to access the medicine. This is one of the more elegant ideas in the space. Continuity of care matters enormously in trauma work, and the standard model of being shuffled to a separate ketamine clinic with a new provider has always felt clinically backwards. Pittsburgh-based and well-funded for a young company, Mindstate is using AI and biochemical data to predict what specific mental states a compound will produce. Their first program is aimed at recreating the empathogenic, MDMA-like state — the warm, connected, defenses-down feeling that has shown such promise for PTSD work. It's ambitious and a little science-fiction. Whether they can actually predict subjective experience from molecular structure is an open question, but the team has impressed people who've looked under the hood. San Francisco-based Osmind is the software backbone for clinics offering ketamine and other psychedelic therapies. It helps practices run, but the long-term value is the data — outcomes data that could eventually convince insurers to cover these treatments, and research data that could refine protocols. Boring on the surface. Probably consequential underneath. Amsterdam-based Synthesis has been around since 2018, running legal psilocybin retreats in the Netherlands and training facilitators. They've adopted a steward-ownership structure — meaning founders and investors are legally bound to the company's mission and social impact, not just returns. That's rare, and it tells you something about how the team is thinking. For readers actually considering a retreat, Synthesis is one of the names that comes up most often in serious conversations about legal, well-organized psilocybin work in Europe. Here's the honest part. None of these companies will sit with you at three in the morning when the medicine is asking you to look at something you've avoided your whole life. That work still happens between you, the plant, and whoever is holding the space. What the industry buildout does change is access. More trained therapists. Better integration support. Clearer information about safety. More legitimate options between the extremes of underground ceremonies with strangers and waiting years for a clinical trial slot. If you're researching plant medicine for addiction recovery, depression, or trauma, the field you're entering today is more navigable than it was even two years ago. A few things that haven't changed and probably won't: Funding announcements are not the same as quality. A startup with $50 million in the bank can still run a mediocre program, and a small lineage-based retreat can offer the most profound experience of your life. When evaluating a retreat, the questions worth asking have less to do with branding and more to do with substance: If a retreat dodges those questions or answers them with marketing language, that tells you something. If they answer them specifically and without defensiveness, that tells you something else. The psychedelic industry is having its moment, and that's mostly good news for people who need help. The molecules, the software, and the venture capital are all interesting — but the actual healing still happens in a room with a person who knows what they're doing. If exploring this further feels right, a curated range of ayahuasca, psilocybin, and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and neither is the part of you that's asking the question.
Psilocybin and Terminal Illness: What Happens When Mushrooms Meet Mortality
There's a particular kind of dread that arrives with a terminal diagnosis. Not the cinematic kind. The quiet kind — the one that sits at the foot of the bed at 4 a.m. and refuses to leave. For decades, mainstream medicine handed people in that situation a script for SSRIs and a referral to a therapist, and called it a day. It rarely worked. How could it? You're not depressed because your brain chemistry hiccuped. You're depressed because you're dying. This is the gap that psilocybin — the active compound in so-called magic mushrooms — has quietly stepped into over the past decade. Clinical trials at Johns Hopkins, NYU, and Imperial College London have followed terminally ill patients through single high-dose psilocybin sessions and tracked what happens after. The results have been strong enough that even cautious researchers have started using words they normally avoid. Words like profound. Words like lasting. The headline numbers are striking. In one widely cited NYU study, roughly 80% of cancer patients who received a single psilocybin session reported clinically significant reductions in depression and anxiety. Six months later, most of them were still better. That's not a typical outcome for any psychiatric intervention — let alone one delivered in a single afternoon. What's more interesting than the percentages is what the patients say. They don't usually describe feeling less depressed in the way an antidepressant might dull the edges. They describe something more like a shift in vantage point. The fear is still there, but it stops running the show. Death stops feeling like a wall and starts feeling like a doorway, or a horizon, or — in the words of one participant I spoke with — "just the next thing that happens." This is where psychedelics get philosophically slippery. Psilocybin doesn't medicate the sadness. It seems to rearrange the relationship the person has with their own situation. That's a different kind of healing, and one our medical system isn't really built to measure. Conventional antidepressants take weeks to begin working and have to be taken daily, often indefinitely. They blunt mood — both the lows and, frequently, the highs. For someone with months left to live, the math is brutal: spend the remaining time on a medication that may or may not work, that flattens emotional range, and that takes a chunk of those final weeks just to titrate up. Psilocybin works differently. A single session lasts about six hours. The acute effects fade by evening. But the psychological shift — the so-called "afterglow" — can persist for weeks or months. Researchers think this is partly because psilocybin temporarily loosens the brain's default mode network, the system responsible for our habitual self-narratives. When that network goes quiet, people often experience what feels like a direct encounter with something larger than themselves. Call it mystical, call it neurological — the effect on subsequent mood is real either way. For someone facing the end of life, that one afternoon can do work that years of talk therapy didn't touch. This isn't recreational mushroom-taking. In a clinical or retreat setting, the structure is deliberate and the work begins long before any substance is consumed. The integration piece matters enormously. A psychedelic experience without integration is like having a dream you forget by lunchtime. The insight evaporates. Done well, integration turns the experience into something the person can keep referring back to long after the chemical has cleared their system. The terminal-illness research is what put psilocybin back on the cultural map, but it's part of a larger story. Plant medicines and psychedelics are being studied for treatment-resistant depression, alcohol use disorder, tobacco addiction, and PTSD. Ayahuasca and ibogaine — the heavier hitters in this family — have shown remarkable results with opioid and stimulant addiction, areas where conventional rehab has a dismal success rate. What ties these studies together is a theme: psychedelics seem to help with conditions where the person is stuck in a story. Addiction is a story. Depression is a story. Terror of death is a story. None of those stories are wrong, exactly — but they become rigid, and the rigidity is what hurts. Psychedelics, used carefully, appear to make the story negotiable again. This is why master plants like ayahuasca and psilocybin-containing mushrooms have been used ceremonially for thousands of years by cultures who never needed a randomized controlled trial to know what they were doing. The science is catching up to something Indigenous traditions have always understood. If you're reading this because someone you love is facing a terminal diagnosis, or because you're sitting with your own — the honest answer is: maybe. Psilocybin-assisted therapy isn't a cure for death or a guarantee of peace. What it offers is a tool. A door. Whether walking through that door is right for any given person depends on health history, mindset, support systems, and the legal landscape where they live. In the United States, psilocybin remains federally illegal, though Oregon and Colorado have created regulated therapeutic frameworks, and several cities have decriminalized personal use. Outside the U.S., countries like Jamaica, the Netherlands, and Mexico host legal or quasi-legal retreats that work specifically with psilocybin and other plant medicines. Quality varies wildly — and so does safety. If you're considering a retreat, do the unglamorous work first. Ask about medical screening. Ask how many facilitators per participant. Ask what integration looks like and whether it's included. Ask about emergency protocols. A reputable center will have clear answers to all of these. A center that gets defensive when you ask is telling you what you need to know. The most striking thing about the terminal-illness research isn't the symptom reduction. It's that participants, when asked months later, frequently rank the psilocybin session among the most meaningful experiences of their lives — comparable to the birth of a child, or marriage. That's an extraordinary claim for a single afternoon in a quiet room. Whatever you make of it, the conversation around psychedelic healing has moved well past whether these compounds do something. They do. The conversation now is about how to do this carefully, ethically, and in service of the people who need it most. For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here.
Public Opinion Is Shifting on Psilocybin and Psychedelic Medicine
Something quietly remarkable has been happening in how Americans talk about psychedelics. Not so long ago, the phrase “magic mushrooms” showed up in conversations alongside tie-dye and Grateful Dead bootlegs. Now it shows up in clinical trials, state ballot measures, and — increasingly — at kitchen tables where someone is wondering whether psychedelics might help a sibling who can't shake their depression, or a parent stuck in addiction, or themselves. Polling backs up the shift. In a Hill-HarrisX survey, roughly 35% of U.S. voters said psychedelic substances like psilocybin have a legitimate medical use. The other 65% disagreed. That split sounds lopsided until you remember the same question, asked a decade earlier, would have produced numbers so small they'd barely register. A third of the country now sees psychedelics as medicine. That's a meaningful cultural moment, and it has direct consequences for anyone weighing whether to attend a psychedelic retreat or pursue plant medicine as part of their healing. The poll cracks open along familiar lines. Among Democrats, 43% accept that psychedelics have medical applications. Independents land at 41%. Republicans sit lower, around 23%. Age matters even more than party. A majority of 18-to-29-year-olds — 53% — say psychedelics belong in medicine. Older cohorts mostly still disagree, though the gap is closing as research piles up. What's driving the younger numbers isn't recreational nostalgia. It's exposure. Younger adults have grown up reading about ketamine clinics, MDMA trials for PTSD, and the steady drumbeat of psilocybin studies coming out of major universities. They've watched friends try microdosing for anxiety. They've seen veterans on podcasts describe ayahuasca and ibogaine as the things that finally cracked their armor when nothing else did. The cultural script has changed, and the poll is the lagging indicator. The science isn't speculative anymore. Imperial College London's Centre for Psychedelic Research ran a head-to-head trial comparing psilocybin therapy with escitalopram — one of the most widely prescribed SSRIs on earth — in patients with moderate-to-severe major depressive disorder. Psilocybin held its own. On several measures, it pulled ahead. Robin Carhart-Harris, who led that work, has been pretty direct about the implication: psilocybin therapy may belong earlier in the treatment ladder for depression, not as the last resort after years of failed pills. That's a significant claim, and it's being taken seriously by regulators and clinicians who, a decade ago, wouldn't have returned the call. Beyond depression, the evidence is mounting across several conditions: None of this means psychedelics are a miracle. They aren't. What they appear to be is a genuinely new class of mental-health tool that works through mechanisms ordinary antidepressants don't touch — neuroplasticity, ego dissolution, emotional reprocessing, and what many practitioners call contact with the master plants themselves. While the federal government still classifies psilocybin and most other psychedelics as Schedule I, the ground is moving locally. Oregon became the first state to legalize psilocybin for supervised therapeutic use. Oregon also decriminalized personal possession of small amounts of psilocybin, alongside Washington, D.C. Denver, Santa Cruz, Oakland, and a growing list of municipalities have either decriminalized or deprioritized enforcement around mushrooms. For readers researching retreats, this matters in practical ways. It means access to legal or quasi-legal psilocybin experiences inside the United States is no longer purely theoretical. It also means the international retreat scene — Peru, Costa Rica, the Netherlands, Mexico, Jamaica — is no longer the only option for people who want a structured, supervised psychedelic experience. That said, the international scene is still where the deepest traditions live, particularly for ayahuasca, San Pedro, and ibogaine. Here's the thing nobody really tells you in the news articles: a polling number doesn't make a retreat safer or more legitimate. Public opinion is a tailwind, not a quality-control mechanism. As psychedelics get more mainstream, the number of retreat centers has exploded — and not all of them are run by people who know what they're doing. If you're weighing whether to book something, a few honest questions to sit with: The angle that keeps drawing new attention is addiction. The standard recovery model — detox, twelve steps, maybe some therapy — works for a lot of people and fails a lot of others. The failure rate is part of why ibogaine clinics in Mexico have waiting lists full of Americans who've tried everything else. It's also why psilocybin-assisted therapy for alcohol use disorder has produced some of the most compelling clinical results in the entire psychedelic field. Plant medicine doesn't replace recovery work. People who treat ayahuasca or ibogaine as a one-shot cure tend to be disappointed, and sometimes worse. But for those willing to do the integration, the therapy, the lifestyle changes — psychedelics can crack open a door that conventional treatment couldn't budge. That's the part the polling numbers don't fully capture: not just that people believe psychedelics have medical value, but that a growing community of people credit them with saving their lives. The 35% number will keep climbing. As more states follow Oregon's lead, as more clinical trials report out, as more veterans and grieving parents and people in long-term recovery tell their stories publicly, the cultural ground will keep moving. The interesting question isn't whether psychedelic medicine becomes mainstream — that's already happening. The question is whether it gets integrated thoughtfully, with proper screening, real training, and respect for the traditions these substances come from, or whether it gets steamrolled by venture capital and turned into another wellness commodity. For now, the people researching retreats are part of that answer. The questions you ask, the centers you support, the standards you hold facilitators to — those things shape what this field becomes. If something in this article has nudged you closer to exploring further, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right container is worth waiting for.
Kambo Safety: The Real Risks Behind the Frog Medicine Trend
A woman in her late thirties walks into a sharehouse on the north coast of New South Wales. She's there to sit for kambo — the secretion of an Amazonian tree frog, dabbed into small burns on her skin. She's done it before. She trusts the woman administering it. A few hours later she's dead on the floor, and her housemate is on the phone to triple-zero because the person running the ceremony doesn't know the number and doesn't own a phone. That's not a hypothetical. That's the case the NSW state coroner ruled on, and the findings should be required reading for anyone thinking about kambo, ayahuasca, or any plant medicine ceremony run outside the bounds of medical oversight. The coroner's language was unusually direct: vulnerable people are putting their trust in self-styled healers who don't have basic first aid training, and the risks of kambo are being underestimated by the people promoting it. If you're reading this because you're weighing a retreat, or because a friend has been raving about how kambo changed their life, slow down. This one's worth thinking through. Kambo is the waxy secretion of Phyllomedusa bicolor, the giant monkey frog of the Amazon basin. Indigenous groups in the region — the Matsés, Katukina, Yawanawá and others — have used it for generations, traditionally before hunting, to sharpen the senses and clear what they describe as panema, a kind of bad luck or heaviness. The frogs are tied to sticks, their backs scraped, and the dried secretion is later applied to small burns on the skin of the recipient. What happens next is intense and fast. Within seconds of application, the peptides in the secretion hit the bloodstream. Blood pressure crashes or spikes. The face swells. People vomit, sometimes violently. There can be diarrhea, sweating, racing heart, panic, a sense of overwhelming heat. The acute phase is usually short — twenty to forty minutes — but those minutes are not gentle. In the West, kambo has been folded into the broader neo-shamanic scene and marketed as a deep physical and spiritual cleanse. You'll see claims about boosting the immune system, clearing addiction, treating depression, even helping with cancer. Here's the part the coroner was explicit about: there is no credible research supporting those medicinal claims. There is, however, documented evidence of harm. Kambo contains a cocktail of bioactive peptides — dermorphin, deltorphin, phyllomedusin, phyllokinin, sauvagine and others. Some are being studied for legitimate pharmaceutical reasons. But the dose in a ceremony isn't measured. The peptide concentration varies frog to frog, batch to batch, practitioner to practitioner. You don't know what you're getting. The physiological strain is real. Kambo can trigger severe hyponatremia (low sodium) if practitioners encourage the loading of water beforehand — a practice that has killed people. It puts stress on the cardiovascular system. It can interact dangerously with prescription medications, particularly antidepressants and blood pressure drugs. People with cardiac conditions, epilepsy, recent surgeries, or who are pregnant should not go near it. And here's the thing — most ceremony providers don't do a serious medical screen. They ask a few questions. They take your word for it. Adverse events documented in the medical literature include seizures, psychosis, kidney injury, esophageal tears from violent vomiting, syndrome of inappropriate antidiuretic hormone secretion, and sudden cardiac death. The Australian Therapeutic Goods Administration eventually classified kambo as a Schedule 10 poison — the most restrictive category, meaning substances of such danger to health that their sale, supply and use should be prohibited. That's not a regulator being squeamish. That's a regulator looking at a death toll. The deeper problem the coroner pointed at isn't kambo itself — it's the parallel economy of self-credentialed healers, priestesses, maestras and shamans that has grown up around plant medicines in the last two decades. Someone takes a two-week course online, designs a website, picks a Spanish or Quechua honorific, and starts charging for ceremonies. This isn't gatekeeping for its own sake. Indigenous traditions that work with kambo, ayahuasca, or peyote involve years of apprenticeship, often a lifetime, with extensive teaching about dosage, contraindications, energetic management, and crucially what to do when something goes wrong. A two-week certificate doesn't replicate that. Neither does charisma. Neither does a beautiful altar. The case in NSW is bleak on this point. The person administering kambo at the fatal ceremony admitted she didn't know the emergency number. She didn't have a phone. The recipient herself had just completed a short practitioner course and was, on the day, leading the session. Two people, neither equipped for what was about to happen, in a sharehouse, with no medical backup. The result is exactly what you'd expect when you remove every safeguard. None of this means every retreat is a death trap. Reputable plant medicine retreats — including ayahuasca centers in Peru, ibogaine clinics in Mexico, and psilocybin retreats in the Netherlands and Jamaica — operate with screening protocols, medical staff on site, and clear emergency procedures. They're not hard to identify if you know what you're looking for. Some questions worth asking any retreat or practitioner before you hand over money: If the answers are vague, defensive, or wrapped in spiritual language designed to make you feel like asking is beneath the work — walk away. A serious practitioner welcomes those questions. They've thought about them more than you have. It would be easy to read a story like this and decide all plant medicine is reckless. That's not quite right either. Ayahuasca, psilocybin, ibogaine, and other psychedelic substances are being studied with increasing seriousness for addiction, treatment-resistant depression, PTSD, and end-of-life anxiety. Some of the early clinical data is genuinely promising. People do find their lives reorganized by these experiences in ways they couldn't access through talk therapy alone. But the gap between a well-run clinical or ceremonial container and a sharehouse ritual run by an under-qualified practitioner is enormous. The medicine isn't the only variable. Set, setting, screening, dosage, facilitation, and aftercare matter as much as the substance itself — often more. The deaths and serious injuries that make headlines almost always involve a breakdown somewhere along that chain, not the molecule acting alone. Kambo is a particular case because the claimed benefits are largely unsupported by research while the physiological risks are well documented. That's a worse risk-benefit profile than most of the classical psychedelics. If you're drawn to the idea of a deep cleanse or a hard reset, there are safer roads to walk down — including ones that involve less dramatic medicines or none at all. The woman at the center of the coroner's findings was, by every account, kind, smart, in pain, and looking for a way through. That's most of the people I meet at retreats. The pull toward plant medicine isn't usually about thrill-seeking — it's about real suffering and the sense that conventional options have run out. That's a sympathetic, human place to be. It's also a place where you're easy to take advantage of. Pain makes us bad consumers. We grasp at the first practitioner who speaks the right language, lights the right candles, says the right things about our wounded inner child. The work of choosing well — slowly, with skepticism intact — is part of the medicine itself. Maybe the first part of it. If you're researching plant medicine because something in your life is genuinely stuck, take the time to do it properly. Read inquest findings. Read peer-reviewed studies. Talk to people who've sat with the practitioner you're considering, ideally years after their ceremony, not weeks. And if you do want to explore vetted ayahuasca, psilocybin, or other plant medicine retreats with proper screening and integration support, you can browse our marketplace here and compare options without the pressure. The medicine isn't going anywhere. Take your time.
Microdosing Psychedelics: What the Science Actually Says So Far
Walk into any co-working space in Berlin, Austin, or Lisbon and you’ll probably bump into someone quietly convinced that a sliver of psilocybin every third morning is the reason they finally stopped doomscrolling and started writing again. Microdosing has crossed from Silicon Valley curiosity into something your accountant might mention over brunch. But underneath the chatter — the books, the podcasts, the carefully labeled tincture bottles — sits a stubborn question: does it actually work, or are people just feeling good about feeling like they’re doing something? The honest answer, after a decade of renewed psychedelic research, is somewhere between “maybe” and “we genuinely don’t know yet.” If you’re researching microdosing as a possible path through depression, addiction, creative stagnation, or the general flatness of modern life, you deserve a real look at the evidence — not the breathless version, and not the dismissive one. A microdose is a fraction of a recreational dose — roughly one-tenth to one-twentieth of what someone would take to have a full psychedelic experience. With psilocybin mushrooms, that usually lands around 0.1 to 0.3 grams of dried fruiting body, compared with the 2 to 3 grams that produce a proper journey. With LSD, the territory is somewhere between 8 and 15 micrograms versus a recreational 100 micrograms or more. The point is that you don’t feel the substance in any classic psychedelic sense. No visuals. No ego dissolution. No couch-melting. That subperceptual quality is the whole pitch. Practitioners report a subtle lift in mood, sharper focus, more empathy with the people around them, occasionally a kind of background creative hum. The protocols vary — James Fadiman’s famous one-day-on, two-days-off schedule is probably the most cited — and most people cycle for four to eight weeks, then pause. Here’s the problem with all of that, scientifically speaking: there is no single agreed definition of a microdose, mushroom potency varies wildly from flush to flush, and LSD is a tasteless, invisible compound whose dose you can only trust if your source is impeccable. Researchers studying this stuff are essentially trying to measure something that hasn’t been standardized yet. The studies pull in two directions, and that’s worth sitting with rather than glossing over. On the optimistic side, a number of large observational studies — including one that tracked roughly 950 psilocybin microdosers against a non-dosing control group over thirty days — have found small-to-medium improvements in mood, anxiety, and general mental health, fairly consistent across age, gender, and whether or not someone walked in with a mental-health diagnosis. That sounds promising, and it lines up with the thousands of anecdotal reports floating around the internet from people who swear it pulled them out of a funk. On the skeptical side, the moment you tighten the methodology, the effect tends to shrink or vanish. In one randomized controlled trial, researchers gave half the participants real psilocybin and half a placebo. Subjectively, the dosing group reported feeling happier and more creative. Some even showed measurable changes on EEG. But on objective measures of creativity, cognition, and well-being? No meaningful difference from placebo. That gap — between how people feel and what tests can actually detect — is the central puzzle. There are two reasonable interpretations: Both can be partly true. Placebo is not nothing — it’s one of the most powerful forces in medicine. But “you’re just imagining it” is a thinner explanation than it sounds when thousands of people are reporting similar shifts. Short-term, low-dose psilocybin appears to be physiologically gentle. Indigenous communities have worked with these mushrooms for centuries. There’s no evidence of organ toxicity at these doses, no addictive pull in the way alcohol or opioids grab people, and the acute risks of a microdose are minimal because you’re not actually having a psychedelic experience. That said, the safety picture isn’t clean, for a few specific reasons: And then there’s the legal layer. In most of the United States and Europe, psilocybin and LSD remain controlled substances. Oregon and a handful of cities have shifted ground, and Colorado is moving in a similar direction, but possession charges are still very real. That alone is a reason a lot of people who would otherwise experiment instead choose to travel — to a legal jurisdiction, to a supervised setting, to a place where the substance is the medicine, not the legal liability. Here’s the part that doesn’t get said enough: most of the impressive clinical results we’ve seen for psychedelics in the last decade — for treatment-resistant depression, PTSD, end-of-life anxiety, alcohol use disorder, tobacco cessation — came from full doses, not microdoses. Big, immersive, sometimes difficult sessions, usually with trained facilitators present. That’s where the headline numbers live. Microdosing is, in a sense, a much more modest proposition. It’s the daily multivitamin to ceremony’s open-heart surgery. If you’re looking for genuine, structural shifts in addiction patterns or deeply rooted depression, the evidence so far points toward higher-dose, supported experiences rather than a sprinkle every Monday and Thursday. That doesn’t mean microdosing is worthless. It may genuinely help some people maintain or extend the benefits of a full experience. It may be useful for milder mood concerns. It may simply be a low-stakes way for someone to introduce psychedelics into their life. But conflating the two — assuming microdosing offers what a ceremonial dose offers, just slower — is a misread of the science. A few practical points, said plainly: On that last point — if what you’re really chasing is meaningful change rather than a productivity tweak, a properly held ceremony with experienced facilitators tends to be where the real work happens. For readers who want to take that further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. The science of microdosing will sharpen over the next few years, and the legal landscape is shifting faster than most people realize. For now, somewhere between the evangelists and the debunkers sits the most useful posture: curious, careful, and genuinely willing to admit that we don’t yet know what we think we know.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
What a Clinical Psilocybin Session Actually Feels Like, Start to Finish
If you've been reading about psilocybin therapy and wondering what actually happens during one of those clinical sessions — the ones the headlines describe in vague, reverent terms — you're not alone. The reporting tends to focus on outcomes: depression lifting, terminal patients making peace with their illness, lifelong drinkers walking away from the bottle. What rarely gets explained is the granular, hour-by-hour reality. The room. The pill. The playlist. The two people sitting quietly nearby while your interior world rearranges itself. I've spent enough time around psychedelic researchers and retreat facilitators to know that the experience is engineered far more carefully than most people assume. Psilocybin, the active compound in magic mushrooms, behaves very differently in a controlled therapeutic container than it does at a music festival. And for anyone weighing whether a retreat or trial might fit their own situation, knowing what those eight or nine hours actually look like matters more than another abstract piece about neuroplasticity. Researchers running modern psilocybin studies — and the reputable plant-medicine retreats that follow their lead — obsess over two words: set and setting. Set is your mindset walking in. Setting is the physical and human environment around you. Get either one wrong and the same dose that produces a breakthrough for one person can produce a long, frightening afternoon for another. This is a big part of why clinical sessions and well-run retreats look nothing like the chaotic mushroom experiences people sometimes describe from college. There's no crowd. No flashing lights. No phone buzzing on the nightstand. The room is usually softly lit, often with a couch, a blanket, eyeshades, and headphones. Two trained sitters — typically with therapy backgrounds — stay with you the entire time, mostly silent, available if you need them. It's worth pausing on that last part. The sitters aren't there to guide you in any active sense. They're there so that if something difficult comes up — a panic spike, a wave of grief, a memory you didn't expect — there's a calm human nearby to remind you that you're safe and that whatever you're feeling will pass. That presence alone changes the chemistry of the experience. Before anyone hands you a capsule, you'll spend hours in conversation. In the Johns Hopkins protocol that's become the template for much of this work, participants typically meet with their two monitors for around eight hours across several sessions before the first dose. You talk about your life. Your reasons for being there. What scares you. What you hope to find. You get walked through what the experience may feel like — the visual shifts, the time distortion, the emotional weather. The instructions participants are given tend to boil down to three words: trust, let go, be open. Simple to say, harder to actually do when you're three hours into a session and your sense of self is dissolving. But repeating those words to yourself in the difficult moments turns out to be surprisingly effective. If you're considering a retreat rather than a clinical trial, the preparation phase is one of the clearest tests of whether the operation is legitimate. Reputable retreats schedule real conversations with you in advance, ask about your medications and mental-health history, screen for contraindications like a personal or family history of psychosis, and don't simply hand you a brew because you paid the deposit. If a place skips that step, walk away. On dosing day, you arrive having eaten lightly. You settle onto the couch. You're given a capsule. In the Hopkins studies, the therapeutic dose was calibrated around 20 milligrams of psilocybin for a 70-kilogram person — roughly 154 pounds. That's enough to reliably produce what researchers carefully call a mystical-type experience, but notably less than the doses associated with difficult trips, which tend to cluster around 30 milligrams or higher. For the first twenty to forty minutes, nothing happens. This is the strangest part for first-timers — the waiting. Then it begins. Most people describe an initial body sensation, a kind of warm pressure, followed by visual softening at the edges of the room. By the one-hour mark you're well inside it. You put on the eyeshades. You put on the headphones. The playlist used in the Hopkins and NYU trials runs about eight hours and weaves together classical pieces by composers like Górecki, Bach, and Beethoven, Indian devotional chants, new-age compositions, and music from around the world. It isn't background. The music becomes structure — something to ride when the experience gets big. One of the practical reasons researchers favor psilocybin over LSD is right there in that timeline. A psilocybin session fits inside a single day. LSD can stretch to twelve hours, which is a long time to hold a therapeutic container — and a long time for a participant to stay in deep process. The patients I've read transcripts of, and the retreat participants I've interviewed over the years, describe remarkably consistent themes. A felt sense that everything is connected. An encounter with grief or fear that somehow doesn't crush them. A perspective shift on a relationship, a regret, a long-held story about themselves. Many describe meeting their illness face-to-face and coming to a kind of truce with it. One woman in the Hopkins cancer-anxiety study, Sherry Marcy, had been living under what she called a cloud of doom after an endometrial cancer diagnosis. After her psilocybin session she described the cloud lifting — reconnecting with her family, her children, her ordinary wonder at being alive. She wasn't cured of cancer. She was returned to her own life while she still had it. That distinction matters. Patrick Mettes, who took part in the parallel NYU trial before dying in 2012, compared the launch of his experience to a space shuttle leaving the clunky trappings of earth behind for the weightlessness above. His widow has said that perspective shift helped them both live fully right up to the end. These aren't promises of healing — they're testimony that the experience can change a person's relationship to suffering, which is often the more honest goal. If you're choosing between a research trial (very hard to get into) and a retreat (much more accessible), it helps to understand how they differ. Clinical sessions are usually one-on-one or two-on-one, indoors, on a couch, with eyeshades and a fixed playlist. Retreats — particularly psilocybin retreats in the Netherlands, Jamaica, or Mexico — tend to run small groups of six to twelve, often combine psilocybin with breathwork, integration circles, and somatic practices, and span several days rather than a single afternoon. Neither format is universally better. The clinical model offers tight safety and screening but limited continuity afterward. The retreat model offers community, often multiple sessions across a week, and dedicated integration time — but quality varies wildly between operators. A few questions worth asking before you book anywhere: The session is the easy part. Integration is where the work actually lives. A profound afternoon under psilocybin can deliver insights at a velocity your normal life isn't built to absorb, and without deliberate follow-through those insights tend to fade into the same drawer where last year's New Year's resolutions went. Good integration usually involves some combination of journaling, conversations with a therapist or coach familiar with psychedelics, body-based practices like yoga or somatic experiencing, and time in nature. It's slow. It's often unglamorous. It's where the cloud-lifting feeling becomes durable change, or doesn't. Anyone selling you a one-and-done miracle is selling you something else. If a supervised psilocybin journey is something you're seriously weighing — for depression, for end-of-life distress, for the kind of stuck pattern that hasn't budged for years — the most useful thing you can do next is read widely, talk to people who've actually been through it, and choose a setting that matches your temperament and your medical reality. For readers who want to take this further, a range of carefully vetted psilocybin retreats can be browsed on our marketplace here. The research is genuinely promising. The experience is genuinely powerful. And the difference between a session that changes your life and one that doesn't usually comes down to the unglamorous details — preparation, container, dose, sitters, integration — long before anyone swallows anything.
How to Dry Magic Truffles Properly: A Practical Storage Guide
If you've ever ordered fresh magic truffles and watched them slowly turn into a sad, slimy lump at the back of the fridge, you already know the problem. Fresh truffles are alive. They breathe, they sweat, and they have a shelf life roughly equivalent to a punnet of strawberries. Drying them isn't just a storage hack — it's the difference between a clean, potent psilocybin experience six months from now and tossing fifteen euros of wasted mycelium into the bin. This guide walks through how to dry magic truffles properly at home, why the method matters for potency, and a few honest caveats most articles skip. I'll also touch on where dried truffles fit into the broader plant medicine conversation — because if you're reading this, there's a decent chance you're already curious about what these little sclerotia can do. Fresh magic truffles — the underground sclerotia of certain Psilocybe species, most commonly Psilocybe tampanensis or Psilocybe hollandica — contain a surprising amount of water. We're talking roughly 70% moisture by weight. That water is great for the truffle while it's growing, but once it's harvested and sealed in a vacuum pack, it becomes a problem. Mould loves moisture. Bacteria love moisture. Your truffles, unfortunately, do not love mould or bacteria. Vacuum-sealed fresh truffles, kept in a cold fridge, will give you maybe four to eight weeks of decent shelf life. After that, even unopened, you'll start to notice spots, slime, or a smell that tells you something has gone very wrong. Once you open the pack, you're looking at a week, tops. Drying solves all of this. Properly dried truffles drop to around 5–10% moisture, which is far too dry for microbial life. Stored well, they'll keep their psilocybin content for a year or more. Some people report decent potency after two years in airtight, light-free storage. The catch — and it's an important one — is that doing it wrong can destroy the active compounds you're trying to preserve. Psilocybin and psilocin are the two main psychoactive compounds in magic truffles. Both are sensitive to heat. Push the temperature too high — above roughly 50°C / 122°F — and you start degrading the very chemistry that makes the truffle worth keeping. People have tried microwaving truffles, baking them in the oven at 100°C, even using hair dryers. The results range from disappointing to genuinely useless. The principle to internalise is simple: dry slowly, at low temperatures, with good airflow. Anything that sounds like a shortcut probably isn't. Drying truffles well takes between 12 hours and several days depending on your method and the local humidity. Plan for that, and you'll be fine. This is the gentlest method, the one that preserves the most potency, and the one most experienced users recommend. It's also the slowest. Break your truffles into pieces no thicker than a peanut. Bigger lumps hold moisture in the centre and risk mould before they dry through. Lay the pieces out on a wire rack or a sheet of kitchen paper, well spaced — they shouldn't touch each other. Put the rack somewhere warm, dry, and dark. A linen cupboard is perfect. Above a radiator (not on it) in winter works well too. Leave them alone for 24 to 48 hours, turning the pieces once or twice. You're looking for what's called "cracker dry" — the truffles should snap cleanly when bent, not bend. If they bend at all, they're not done. This stage is where people get impatient and ruin their batch. Resist that urge. If you live somewhere humid — coastal climates, the UK in autumn, basically anywhere damp — pure air drying can stall. The truffles get to a leathery state and just sit there, slightly tacky, refusing to crisp up. A small desk fan solves this beautifully. Same setup as before — broken truffles on a wire rack — but with a fan blowing across them on the lowest setting. Don't aim hot air at them. Just moving room-temperature air is enough. This usually cuts drying time to 12–18 hours. Once they're cracker dry, you move to the most important step: the final cure. Here's where most home dryers stop, and it's why their truffles lose potency faster than they should. Cracker-dry truffles still contain a small percentage of residual moisture — enough to slowly degrade psilocybin over months in storage. The cure removes that last bit. Put your dried truffles in an airtight jar with a desiccant — food-grade silica gel sachets work, or you can buy small calcium chloride canisters from any homebrewing or food-storage supplier. The desiccant should be in its own little container or wrapped in a bit of paper towel so it doesn't touch the truffles directly. Seal the jar. Leave it for another 24 to 48 hours. What you'll get at the end is what people sometimes call "bone dry" — truffles so dehydrated they're brittle and almost weightless. This is the state you want for long-term storage. Stored in a cool, dark place in a sealed container with a fresh desiccant, they'll hold their potency for a year easily, often longer. One thing worth mentioning, because it trips up a lot of people: a dried truffle is much lighter than a fresh one. If a recipe or experience report references "15 grams of fresh truffles", that's roughly equivalent to 4–5 grams dried, since you've removed about 70% of the original weight as water. The psilocybin content per truffle hasn't changed — you've just concentrated it into less mass. So if you're used to dosing by fresh weight and you switch to dried, scale down accordingly. People have surprised themselves badly by treating dried weights like fresh ones. A scale that reads to 0.1g is essential here, not optional. Magic truffles occupy an interesting legal grey area — in the Netherlands they're sold openly because they were never specifically banned the way the mushroom fruiting bodies were. For people curious about psilocybin but unable or unwilling to travel for a formal psychedelic retreat, truffles have become a kind of accessible entry point. They're milder gram-for-gram than dried mushrooms, more predictable in dose, and legal to purchase in a handful of European countries. That said, doing this work alone in your living room is a different proposition from doing it with experienced facilitators in a held container. Psilocybin can surface difficult material, and integration matters. If you're drawn to plant medicine for something deeper than curiosity — addiction patterns you can't shake, depression that hasn't responded to anything else, trauma you can't outrun — a structured retreat is usually a better starting point than a solo session with dried truffles from your cupboard. For readers who want to take this further with proper support, a range of curated psilocybin and plant medicine retreats can be browsed on our marketplace here. Either way: dry your truffles properly, store them better than you think you need to, and treat what's in the jar with the respect it deserves.
The Psychedelic Gold Rush: What the Wall Street Bet on Plant Medicine Means for Retreat-Seekers
A few years back, a former Goldman Sachs partner stood in front of a room full of hedge fund executives in Miami and told them, with the casual confidence of someone who's already placed his chips, that psychedelics would be the next short-term bubble. He wasn't talking about ayahuasca ceremonies in the Peruvian jungle. He was talking about IPOs, FDA pathways, and patent portfolios. And he was right — sort of. That moment, more than almost any other, marked the point where psychedelics stopped being a fringe wellness curiosity and became a serious investment category. Compass Pathways did go public. ATAI Life Sciences followed. MindMed listed on the Nasdaq. Billions of dollars poured into research labs trying to figure out how to turn magic mushrooms and ibogaine into prescription medicine. And for people quietly researching whether to book a retreat for their depression, addiction, or grief, this matters more than you might think. Here's the thing, though. The Wall Street story and the retreat-seeker story are not the same story. They share vocabulary. They sometimes share science. But they're aimed at completely different outcomes, and confusing one for the other can lead you to make a bad decision about your own healing. The bull case is straightforward. Depression affects hundreds of millions of people globally. Conventional antidepressants help maybe a third of patients meaningfully, and roughly another third get partial relief. That leaves an enormous population — people with treatment-resistant depression, PTSD, addiction, end-of-life anxiety — for whom modern psychiatry has very little to offer. Early clinical trials with psilocybin, MDMA, and ibogaine have produced results that, frankly, look almost too good. Single-digit numbers of sessions producing remission rates that pharmaceutical companies usually dream about. If you're an investor, that's a market measured in tens of billions. If you're a patient, it's something else entirely — it's the first piece of genuinely new mental health science in fifty years. Both things can be true at once. The awkward part is that they create very different incentives. Pharmaceutical companies want patentable molecules, controlled dosing, standardized protocols, and reproducible outcomes. They want a pill, or as close to a pill as the FDA will allow. They are not, generally speaking, interested in a Shipibo curandero singing icaros over you for six hours in a wooden maloca. That's a feature, not a bug, of how drug development works. But it does mean the medicalized version of psychedelics that eventually reaches your psychiatrist's office will look almost nothing like a traditional plant medicine retreat. What Novogratz called an awakening — the recognition that ayahuasca, psilocybin mushrooms, and the iboga root from West Africa have real medicinal potential — isn't new to anyone who's spent time in indigenous healing traditions. The Shipibo, the Bwiti, the Mazatec, and dozens of other cultures have known this for centuries. The novelty is that Western institutions like Johns Hopkins and Imperial College London are now publishing the data that confirms what these traditions have always claimed. This is where master plants come into the conversation. In the Amazonian tradition, plants like ayahuasca, chacruna, bobinsana, and tobacco aren't just chemicals — they're considered teachers, beings with their own intelligence that work with you over time through a structured process called dieta. A retreat-seeker considering ayahuasca needs to understand this framing exists, even if they don't fully buy into it, because the people pouring the brew at most reputable retreats absolutely do. For addiction recovery in particular, the picture has been quietly remarkable. Ibogaine, derived from the iboga root, has shown the ability to interrupt opioid dependence in ways no pharmaceutical has matched — often in a single, intense session. Ayahuasca centers in Peru and Costa Rica have hosted people fighting alcohol dependence, cocaine addiction, and process addictions with outcomes that, while not formally measured the way a clinical trial would measure them, are striking enough that researchers have started taking them seriously. The investment boom is reshaping the retreat landscape in ways most prospective participants don't see. Some changes are good. Some are decidedly not. On the good side: more public conversation has meant more transparency, better screening protocols at reputable retreats, and a slow professionalization of integration services. Five years ago, finding a therapist who would seriously discuss your ayahuasca experience without recommending an inpatient psych ward was difficult. Now they exist in most major cities. That's progress. On the less good side: money attracts opportunists. The number of new retreats opening every year has exploded, and not all of them are run by people with the experience, training, or ethics the work requires. I've sat in ceremonies led by maestros with forty years in the tradition, and I've heard horror stories about weekend operators who learned the medicine from a YouTube playlist. The gap between those two ends of the spectrum is enormous and, for an untrained eye, surprisingly hard to spot from a glossy website. Here's what I'd actually look at when researching a psychedelic retreat: Cost ranges vary wildly. A week-long ayahuasca retreat in Peru typically runs anywhere from $1,500 at simpler centers to $4,500 at more elaborate ones. Ibogaine clinics, because they require medical supervision, sit higher — usually $5,000 to $10,000 for a treatment program. Psilocybin retreats in the Netherlands, Jamaica, or Costa Rica generally fall between $2,000 and $5,000. None of this is cheap, and the cheap options often aren't the bargain they appear to be. One thing the Wall Street narrative tends to flatten is the difference between taking a psychedelic compound in a clinical setting and sitting in ceremony with a plant medicine. Both can be healing. They are not the same experience. The clinical model, which is what Compass Pathways and similar companies are building toward, looks like this: you arrive at a medical office, take a measured dose of a synthesized molecule, lie on a couch with eyeshades and a curated playlist, and have a trained therapist sit with you. It's regulated, repeatable, and increasingly likely to be covered by insurance. For people with severe treatment-resistant depression who would never set foot in a jungle lodge, this model is going to be a genuine breakthrough. The ceremonial model is something else. You're typically away from home for a week or more. You eat a restricted diet for days beforehand. You drink the medicine in a group, often through the night, accompanied by songs and prayers that come from a specific cultural tradition. You purge — usually physically, sometimes emotionally, often both. The context, the community, and the cultural container are considered as important as the substance itself. Neither approach is universally better. They serve different needs. If your goal is to address clinical depression in a structured medical setting, the clinical path may suit you. If your goal is something messier — a confrontation with patterns you can't seem to break, grief you haven't been able to metabolize, a sense that your life has drifted from anything resembling meaning — the ceremonial path tends to do that work in a way no clinic currently replicates. Was Novogratz right that psychedelics would become a short-term bubble? Partly. Several listed psychedelic companies have had brutal stock performance since their initial euphoria. The science, meanwhile, has continued to mature. MDMA-assisted therapy for PTSD came close to FDA approval and may yet get there. Psilocybin therapy programs are advancing through trials. Ibogaine is finally getting serious clinical attention in the United States after decades of being treated as fringe. For the retreat-seeker, the financial drama is mostly noise. What matters is that the cultural permission to talk about these experiences is wider than it's ever been, the integration ecosystem is more developed, and the research validating what indigenous traditions have long claimed continues to accumulate. None of that guarantees a good experience for you personally. But it does mean you're not stepping into the unknown alone the way someone in 1995 would have been. If something in this piece has nudged you closer to actually doing the work rather than just reading about it, a curated selection of ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine, whichever one you choose, will still be there when you're ready.
Kambo Ceremony, Round Two: Sitting With Fear and the Frog
The second time around, I thought I knew what I was walking into. I didn't. That's the thing about kambo — and most plant medicine, really. You show up with one set of expectations and the medicine quietly hands you a different agenda. My first kambo journey had been intense but luminous. I left it feeling scrubbed clean from the inside, hyper-aware of what my body wanted to eat, drowning in something close to self-love. So when two old friends — both deep in shamanic ceremony for years — invited me over for an afternoon sit, I said yes almost reflexively. Sunday afternoon. Bike ride away. Empty calendar. Why not? Be careful what you wish for. My friend opened the door and I felt the fear arrive before I'd even taken off my shoes. Bodies remember. Mine remembered the bottles of water lined up like soldiers, the bucket waiting nearby, the heat that climbs up the arm and settles inside the skull. For a second I genuinely thought about turning around. Going home. Saying I forgot something. But I was there. The soup was on the stove. My friends were smiling. And honestly — last time had been beautiful. Hard, yes. But beautiful. How much worse could a second round be? The four of us sat in a circle inside what used to be a classroom, now part of an artist commune. Feathers on the walls, dream catchers, the smell of old wood. A friend handed me a small carved frog made of green stone — jade or something similar. Whoever held the frog got to speak. The others listened. It's a simple device but it does something to a room. “What's your intention?” he asked. Usually I arrive with a clear one. I'd journaled, I'd thought it through, I knew exactly what I wanted to look at. This time I had nothing. I closed my eyes and waited. The answer surfaced almost on its own: I want to learn how to sit with fear. Not push it away, not perform around it, not make anyone else responsible for it. Just sit with it. I passed the frog along and we smiled at each other across the circle. There's a particular kind of intimacy in admitting your fear out loud to people who aren't going to flinch. Before we got to the kambo, my friend offered rapé. I'd only heard about it a few weeks earlier, which felt like one of those convenient synchronicities the universe occasionally throws your way. For anyone who hasn't come across it: rapé (pronounced ha-PAY) is a finely ground powder made from tobacco mixed with the ashes of certain sacred trees. It's blown into your nostrils through a V-shaped wooden pipe by another person — you can't really self-administer it properly. The active compounds absorb through the nasal tissue and reach the brain almost immediately. She knelt in front of me, knees touching mine, and tipped a small mound of green powder into the pipe. Deep breath in. The pipe against my left nostril. A short, sharp exhale from her end — and the powder hit. The sting climbed straight into my skull. My left eye watered immediately. We did the right nostril next. Then I sat there, mouth open, drooling into the bucket like a baby, while a hot wave rolled up through my torso and into my head. What I didn't expect was the sense of power. Not arrogance — more like a clean, undeniable awareness that there was a serious reservoir of strength inside me. I wanted to bottle it for the days I feel small. The rush peaked, then softened, then left me with this quiet, slightly nauseous clarity. The colors in the room had brightened. The inner critic that usually narrates everything had simply gone quiet. Beautiful, actually. Worth mentioning if you've never tried it: the experience varies wildly depending on the blend, the moment, and who's blowing it. Some people get a clean grounding; others end up vomiting. It's not a party drug. “How many dots, and where?” my friend asked. Traditionally men get them on the upper left arm, women on the lower left leg. He left it open. I noticed my left hand was already gripping my right shoulder, almost without my deciding. So — four dots, right shoulder. He nodded; he'd been thinking the same number. The kambo process itself is straightforward and strange. You drink a lot of water — at least a liter, ideally more — to give the body something to purge. The points are made by lightly burning the top layer of skin with the tip of a smoldering stick. Then a small amount of the frog secretion is placed on each burn. The medicine enters through the lymphatic system, not the bloodstream, which is part of what makes it so fast. I started purging before he'd even finished the burns. The fear I'd named as my intention was already climbing my throat. I made the bucket just in time. My friend laughed gently and told me to keep drinking. So I did. Another liter or so, until any more would have come straight back up. The first dot of medicine touched my skin and the heat went everywhere at once. Down my arm. Up my neck. My face felt like it was inflating. The inside of my mouth swelled — I was briefly relieved I could still breathe through it. My head dropped onto my knee and the fear flooded back in full strength. And here's the part I want to be honest about, because it's the part nobody really markets: I noticed, in that moment, how badly I wanted someone to rescue me. To hold my hand. To say something soothing. To take the feeling away. My friends had offered all of it — they were sitting right there. But I had a choice. Reach for relief, or stay. I stayed. Not heroically. Just stubbornly. I knew the wave would pass. I knew there was no story that needed solving, no version of me that needed saving. I just had to hold my own knees and breathe. After what was probably twenty minutes but felt longer, I crawled to a couch a few meters away. Could not find a comfortable position to save my life. Tried every side, gave up, ended up cross-legged with sun on my closed eyelids. The intensity slowly drained out. My head still felt enormous, but the fear had loosened its grip. When I finally touched my lips, they were not my lips. Kambo sometimes leaves you with what facilitators call frog face — puffy lips, swollen eyelids, the works. It fades within a day or so. I looked in the mirror and laughed. I was grateful I didn't have plans. The whole afternoon had compressed into maybe ninety minutes of actual ceremony, and now we were drifting back into the sharing circle, this time with a huge stuffed frog as the talking object. I looked at the three people in the room and felt like I could actually see them — past the small talk, past the personality, into whatever quiet thing was underneath. That part doesn't translate to writing very well. You either know the feeling or you don't yet. Here's what I wasn't expecting. After my first kambo round, the afterglow had been delicious — clean senses, intuitive eating, a steady hum of self-love. This time, the medicine handed me my intention with both hands. Every fear I had agreed to look at came marching through, one after another, for an entire week. I'm used to emotional weather. This was a storm. But each time a fear surfaced, I remembered the imprint from the ceremony — that I didn't need to leak it onto anyone. I didn't need to find someone to blame, or someone to soothe it for me. I could ask: is this thought actually true? Am I currently making someone else responsible for my own discomfort? It's a useful little knife to carry around. None of which means I sat there silently swallowing everything. Boundaries matter. Desires matter. Expressing them matters. But what happens after you express them isn't yours to control. When you make yourself vulnerable, you're also making yourself reachable — and reachable means occasionally hurt. The medicine didn't make that easier. It just made it more obviously worth it. A few honest notes, because I get asked. Kambo isn't psychedelic — there's no visionary component, no altered headspace in the way ayahuasca or psilocybin produces. It's somatic. Physical. Brutally physical for about thirty minutes. The work happens in the body and in whatever you're forced to confront while your body is busy. It also isn't risk-free. There are real contraindications — heart conditions, low blood pressure, pregnancy, certain medications, recent surgery — and a responsible facilitator will ask about all of them before you sit. If they don't ask, don't sit with them. Hydration matters. Fasting beforehand matters. Sitting with experienced people matters. This is one of those medicines where the difference between a good practitioner and a careless one is significant. And the afterglow, as I learned, isn't guaranteed to be pleasant. Sometimes the medicine clears space; sometimes it surfaces everything that was sitting in that space. Both are useful. Neither is comfortable. If something in this resonates and you want to take a closer look, a range of curated kambo and plant-medicine ceremonies can be explored on our marketplace here. Whatever you choose, choose slowly. The frog will wait.
Psychedelics as Medicine: Where Psilocybin, MDMA and Ayahuasca Stand Now
A few years ago, suggesting that magic mushrooms might be on a regulatory glide path toward becoming an approved medicine would have gotten you a polite eye-roll at most dinner parties. Today, that same conversation is happening at Davos, in peer-reviewed journals, and in the offices of biotech investors who quietly want a piece of the action. Psychedelics — once shorthand for sixties counterculture — have re-entered medicine through a side door, and they brought ayahuasca, psilocybin, MDMA and a few other plant-based and synthetic compounds with them. If you're somewhere on the spectrum between curious and quietly desperate — maybe weighing a retreat for depression, addiction, or trauma that hasn't budged with conventional care — it's worth understanding what's actually going on. Not the hype version. The real one. The shift didn't happen overnight. It started with small, almost stubborn pilot studies. Cancer patients facing terminal diagnoses were given a single supervised dose of psilocybin and many of them described, weeks later, that their fear of dying had loosened its grip. Combat veterans with treatment-resistant PTSD sat through MDMA-assisted therapy sessions and reported that the intrusive flashbacks finally let them sleep. And people with depression that hadn't responded to multiple antidepressants tried ayahuasca in clinical settings — the same brew Amazonian healers have used for generations — and some of them came out the other side genuinely different. That's the pattern researchers keep pointing at. These compounds appear to do something for the people who haven't been helped by anything else. And the dose required to see results is, in most cases, startlingly small. One or two supervised sessions. Not a daily pill for life. The phrase that keeps coming up among scientists in the field is cautious optimism. As one prominent neuroscientist at Imperial College London put it during a session on the new science of psychedelics: the climate's looking good. Which, coming from a researcher who has spent his career on this, is roughly the equivalent of a normal person yelling from a rooftop. Two compounds are leading the regulatory pack, and they treat very different things. Psilocybin — the active molecule in magic mushrooms — has shown its sharpest results in severe depression, particularly the treatment-resistant kind where someone has tried four, five, six different antidepressants without meaningful change. In supervised sessions, a single dose alongside therapy seems to crack something open. Not a cure, exactly. More like a window that lets the patient see their own situation from outside it, long enough to make the changes that the depression had been blocking. MDMA — yes, the same molecule that's been dancing through clubs for forty years — is being studied as an adjunct to talk therapy for post-traumatic stress disorder. The drug doesn't do the work alone. It quiets the fear response just enough that the patient can actually talk about what happened without dissociating or shutting down. The therapist does the rest. Other compounds are on the docket too. Ketamine, a partial psychedelic, is already being prescribed off-label for depression in many countries. Ibogaine — derived from an African shrub — is being explored for opioid addiction, often in retreat settings outside the US because of its legal status. And ayahuasca itself, the South American brew of Banisteriopsis caapi vine and DMT-containing leaves, has its own growing research footprint, especially around depression and addiction. This is the question I get asked most, usually in a quieter voice than the others. The honest answer: the evidence is genuinely promising, but it's also still early, and the gap between a clinical trial and a jungle retreat is wider than people want to admit. What we know: The mechanism, as best researchers can tell, isn't that the substance scrubs the addiction away. It's that a well-prepared psychedelic experience seems to give people a kind of bird's-eye view of their own life — their relationships, their pain, the patterns they've been re-enacting. From up there, the addiction often looks less like an identity and more like a strategy that stopped working. That insight is what people then carry into the difficult work of staying changed. None of this means a single ceremony will fix anything. People who do well with plant medicine for addiction almost always combine it with therapy, community, and a meaningful change in daily life. The retreat is a pivot point, not a finish line. I'd be doing you a disservice if I painted this as risk-free. It isn't, and reputable facilitators will say so before they say anything else. A few things worth knowing if you're considering a psychedelic retreat: Assume you've decided this is worth exploring. Here's the rough shape of due diligence I'd want you to do before handing over any money. Medical screening. A serious retreat will ask about your medications, mental-health history, cardiovascular health, and family psychiatric history before they'll take your deposit. If the intake process is just a credit card form, that's a red flag. Move on. Facilitator lineage and training. Whether the leaders trained in a traditional Amazonian context, a Western therapeutic model, or both, they should be able to explain it clearly. Vague answers — "I've been called to this work" without specifics — are worth pausing on. Group size and ratio. Twelve participants with two facilitators is reasonable. Thirty participants with two facilitators is a crowd, not a ceremony. Ask before you book. What happens after. Is there integration support included? A group call two weeks out? Recommended therapists in your home country? The aftermath is where many people quietly struggle, and the best retreats build for it. Honest pricing. A well-run plant-medicine retreat generally runs somewhere between $1,500 and $5,000 for a week, depending on country, accommodation, and reputation. Substantially cheaper often means corners cut. Substantially more expensive often means you're paying for thread count, not better outcomes. The current expectation among researchers is that the first formally approved psychedelic medicine — most likely psilocybin for severe depression, or MDMA for PTSD — will be available through regulated clinical channels within the next few years in several countries. The investment money has arrived. The clinical evidence keeps strengthening. The cultural conversation has shifted from are these drugs? to how do we deliver them responsibly? That doesn't mean retreats become obsolete. For many people — especially those drawn to traditional Amazonian ceremonies, or those whose conditions don't map neatly onto a clinical diagnosis — the retreat path will remain meaningful long after psilocybin shows up at the local clinic. The two worlds are different doors into related rooms. What's changed is that the conversation is finally serious. You're no longer choosing between fringe ceremony and skeptical doctor. You're choosing among several legitimate paths, each with its own trade-offs, and you get to pick the one that fits your situation. If something here speaks to you, the ayahuasca and psychedelic retreats discussed across the wider plant-medicine community can be browsed and booked on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right retreat for you is the one you booked after asking every question, not the one you booked because the calendar pressured you into it.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
